Alvin P. Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alvin P. Chan has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Q. de Aguiar Vallim
Division of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center (JCCC), University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
5 shared publications Kevin J. Williams
4 shared publicationsElizabeth J. Tarling
Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center (JCCC), University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA
3 shared publicationsKelsey E. Jarrett
Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA
3 shared publicationsMadelaine C. Brearley-Sholto
3 shared publicationsAlireza Sedarat
Division of Digestive Diseases, Department of Medicine Ronald Reagan UCLA Medical Center Los Angeles California USA
2 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Wiley in JPGN Reports
Stepwise administration of de novo ketogenic parenteral nutrition for refractory epilepsy during prolonged bowel rest following duodenal perforation
Ketogenic diet is an established therapy for pediatric patients with intractable epilepsy. By shifting energy metabolism from glucose to fat, the diet increases the production of ketone bodies, which alters neuronal excitability and modulates neurotransmitter signaling, thereby raising the seizure threshold. In critically ill children who are unable to tolerate enteral feeds, ketogenic parenteral nutrition (kPN) offers a valuable alternative to the standard ketogenic diet. However, its use has been underutilized and challenged by a lack of standardized protocols. In this report, we present a stepwise approach for initiating kPN in a ketogenic diet‐naive toddler with refractory epilepsy and bowel dysfunction.
- 30 October 2026
- Published by Wiley in JPGN Reports
Open AccessStepwise administration of de novo ketogenic parenteral nutrition for refractory epilepsy during prolonged bowel rest following duodenal perforation
Ketogenic diet is an established therapy for pediatric patients with intractable epilepsy. By shifting energy metabolism from glucose to fat, the diet increases the production of ketone bodies, which alters neuronal excitability and modulates neurotransmitter signaling, thereby raising the seizure threshold. In critically ill children who are unable to tolerate enteral feeds, ketogenic parenteral nutrition (kPN) offers a valuable alternative to the standard ketogenic diet. However, its use has been underutilized and challenged by a lack of standardized protocols. In this report, we present a stepwise approach for initiating kPN in a ketogenic diet‐naive toddler with refractory epilepsy and bowel dysfunction.
- Open Access
- 25 October 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 556
Theratyping for personalized medicine across cystic fibrosis disease models
In the era of CFTR modulators, cystic fibrosis (CF) is being profoundly reshaped for treatment-eligible individuals. Theratyping, an ex vivo strategy assessing individual responses to CFTR modulators, supports precision medicine, particularly for rare variants where conventional trials are limited. In this Review, we discussed advances in CF disease modelling, highlighting strengths, limitations and translational relevance. We also outlined future directions aligned with the Replacement, Reduction, and Refinement (3 R) ethical principles in animal research, including organ-on-a-chip technologies, to improve mechanistic insight and preclinical predictivity. CF research offers therefore a paradigmatic framework for therapeutic innovation in other rare genetic diseases.
- 25 October 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 556
Open AccessTheratyping for personalized medicine across cystic fibrosis disease models
In the era of CFTR modulators, cystic fibrosis (CF) is being profoundly reshaped for treatment-eligible individuals. Theratyping, an ex vivo strategy assessing individual responses to CFTR modulators, supports precision medicine, particularly for rare variants where conventional trials are limited. In this Review, we discussed advances in CF disease modelling, highlighting strengths, limitations and translational relevance. We also outlined future directions aligned with the Replacement, Reduction, and Refinement (3 R) ethical principles in animal research, including organ-on-a-chip technologies, to improve mechanistic insight and preclinical predictivity. CF research offers therefore a paradigmatic framework for therapeutic innovation in other rare genetic diseases.
- Open Access
Timing of Parenteral Nutrition in Neonates, Infants, and Children: Current Evidence, Circadian Considerations, and Emerging Directions
Despite advances in parenteral nutrition (PN) formulations, the temporal aspects of PN delivery are less defined. This review synthesizes evidence on the optimal timing of PN initiation, duration, and delivery within the 24-h day in pediatric populations. Evidence suggests that the optimal timing of PN initiation varies by age and clinical context. While early PN remains standard practice for very preterm and very low birth weight infants, delaying PN has been associated with improved outcomes in critically ill children. Continuous PN is routinely initiated in neonates and critically ill children to minimize fluid and metabolic fluctuations, whereas cyclic PN is generally used in older infants and children who are clinically stable to allow infusion-free periods and greater mobility. Despite the widespread use of overnight PN infusions in both the hospital and home settings, the clinical implications of aligning PN delivery with endogenous circadian rhythms remain very limited. Future studies should establish optimal temporal strategies for different pediatric populations and determine whether optimizing the timing, infusion pattern, and circadian alignment of PN delivery improves growth, development, metabolic health, and quality of life.
Open AccessTiming of Parenteral Nutrition in Neonates, Infants, and Children: Current Evidence, Circadian Considerations, and Emerging Directions
Despite advances in parenteral nutrition (PN) formulations, the temporal aspects of PN delivery are less defined. This review synthesizes evidence on the optimal timing of PN initiation, duration, and delivery within the 24-h day in pediatric populations. Evidence suggests that the optimal timing of PN initiation varies by age and clinical context. While early PN remains standard practice for very preterm and very low birth weight infants, delaying PN has been associated with improved outcomes in critically ill children. Continuous PN is routinely initiated in neonates and critically ill children to minimize fluid and metabolic fluctuations, whereas cyclic PN is generally used in older infants and children who are clinically stable to allow infusion-free periods and greater mobility. Despite the widespread use of overnight PN infusions in both the hospital and home settings, the clinical implications of aligning PN delivery with endogenous circadian rhythms remain very limited. Future studies should establish optimal temporal strategies for different pediatric populations and determine whether optimizing the timing, infusion pattern, and circadian alignment of PN delivery improves growth, development, metabolic health, and quality of life.
- Open Access
- 27 July 2026
- Published by Elsevier in Journal of Lipid Research
- Vol. 67 (8)
Intestinal lipase inhibition uncouples diet-induced obesity from MASH by remodeling the hepatic lipidome in mice
- 27 July 2026
- Published by Elsevier in Journal of Lipid Research
- Vol. 67 (8)
Open AccessIntestinal lipase inhibition uncouples diet-induced obesity from MASH by remodeling the hepatic lipidome in mice
- Open Access
- 26 June 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (3) , 104658
A protocol for noninvasive quantification of dietary fat absorption in mice
- 26 June 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (3) , 104658
Open AccessA protocol for noninvasive quantification of dietary fat absorption in mice
- Open Access
- 19 March 2026
- Published by Wiley in JPGN Reports
- Vol. 7 (2) , 374-376
Pancreatic solid pseudopapillary neoplasm mimicking a pseudocyst in a young female with acute pancreatitis
Solid pseudopapillary epithelial neoplasm (SPEN) of the pancreas is a rare, low‐grade pancreatic neoplasm that is uncommon in the pediatric population. We present the case of previously healthy 11‐year‐old girl with a pancreatic mass initially misdiagnosed as a pseudocyst, later confirmed to be a SPEN. This report highlights key clinical and imaging features distinguishing SPEN from pancreatic pseudocysts and underscores the importance of maintaining a broad differential diagnosis when the clinical course is atypical.
- 19 March 2026
- Published by Wiley in JPGN Reports
- Vol. 7 (2) , 374-376
Open AccessPancreatic solid pseudopapillary neoplasm mimicking a pseudocyst in a young female with acute pancreatitis
Solid pseudopapillary epithelial neoplasm (SPEN) of the pancreas is a rare, low‐grade pancreatic neoplasm that is uncommon in the pediatric population. We present the case of previously healthy 11‐year‐old girl with a pancreatic mass initially misdiagnosed as a pseudocyst, later confirmed to be a SPEN. This report highlights key clinical and imaging features distinguishing SPEN from pancreatic pseudocysts and underscores the importance of maintaining a broad differential diagnosis when the clinical course is atypical.
- Open Access
- 11 December 2025
- Published by Elsevier in Cell Metabolism
- Vol. 38 (2) , 263-280.e10
Bile acids regulate lipid metabolism through selective actions on fatty acid absorption
- 11 December 2025
- Published by Elsevier in Cell Metabolism
- Vol. 38 (2) , 263-280.e10
Open AccessBile acids regulate lipid metabolism through selective actions on fatty acid absorption
- 17 June 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 485-496
Evidence‐based review of the nutritional treatment of obesity and metabolic dysfunction‐associated steatotic liver disease in children and adolescents
The growing pediatric obesity epidemic has paralleled the surge in metabolic dysfunction‐associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated steatohepatitis. It develops due to nutritional imbalances, microbiome dysbiosis, gene regulation, hormonal changes, and environmental factors like food deserts, low activity level, and an unhealthy lifestyle. The prevalence of MASLD and obesity is rising every year. Lifestyle changes remain the mainstay treatment for obesity and MASLD. Per the 2023 American Association for the Study of Liver Diseases Practice Guidance on MASLD, achieving ≥5% weight loss can reduce hepatic steatosis, ≥7% weight loss can reduce hepatic inflammation, and ≥10% weight loss can reduce liver fibrosis. Therefore, nutritional interventions can be a powerful tool to help correct metabolic dysfunction and promote healthy weight loss. Current endorsed nutritional interventions for weight loss or MASLD include the Mediterranean diet, low glycemic/low carbohydrate diet, plant‐based diet/anti‐inflammatory diet, ketogenic diet, and intermittent fasting. This review provides evidence‐based insights into current nutritional interventions for children and adolescents with obesity and MASLD to help guide pediatric gastroenterologists in making the best dietary‐based recommendations in clinical practice.
- 17 June 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 485-496
Evidence‐based review of the nutritional treatment of obesity and metabolic dysfunction‐associated steatotic liver disease in children and adolescents
The growing pediatric obesity epidemic has paralleled the surge in metabolic dysfunction‐associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated steatohepatitis. It develops due to nutritional imbalances, microbiome dysbiosis, gene regulation, hormonal changes, and environmental factors like food deserts, low activity level, and an unhealthy lifestyle. The prevalence of MASLD and obesity is rising every year. Lifestyle changes remain the mainstay treatment for obesity and MASLD. Per the 2023 American Association for the Study of Liver Diseases Practice Guidance on MASLD, achieving ≥5% weight loss can reduce hepatic steatosis, ≥7% weight loss can reduce hepatic inflammation, and ≥10% weight loss can reduce liver fibrosis. Therefore, nutritional interventions can be a powerful tool to help correct metabolic dysfunction and promote healthy weight loss. Current endorsed nutritional interventions for weight loss or MASLD include the Mediterranean diet, low glycemic/low carbohydrate diet, plant‐based diet/anti‐inflammatory diet, ketogenic diet, and intermittent fasting. This review provides evidence‐based insights into current nutritional interventions for children and adolescents with obesity and MASLD to help guide pediatric gastroenterologists in making the best dietary‐based recommendations in clinical practice.
- 1 April 2025
- Published by American Academy of Pediatrics (AAP) in Pediatrics in Review
- Vol. 46 (4) , 219-223
Chest Pain and Weight Loss in a 10-Year-Old Girl
- 1 April 2025
- Published by American Academy of Pediatrics (AAP) in Pediatrics in Review
- Vol. 46 (4) , 219-223
Chest Pain and Weight Loss in a 10-Year-Old Girl
- 21 July 2024
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 79 (3) , 460-472
From the kitchen to the medicine cabinet: Examples of food products and supplements used for therapeutic intent
“Food as medicine” has existed for centuries as the foundation of health for many cultures around the globe. It is a practice built on the knowledge that food and diet play important roles in disease prevention and management. Foods that claim to have therapeutic properties are often referred to as functional foods. These foods contain a number of nutritional and nonnutritional compounds that can interact with pharmacologically relevant receptors, either directly or indirectly via their metabolites, to regulate cellular biochemical processes. Although opinions are changing, the concept of food as a therapeutic intervention goes against conventional Western medicine. To provide guidance to clinicians interested in using these products, members of the Food as Medicine working group of the Nutrition Committee NASPGHAN, as part of a two‐part review series, have created summaries of several frequently used nutritional products for therapeutic intent (i.e., fermented foods, fiber, and long‐chain omega‐3 fatty acids) that includes indications, doses, and caveats. Gaps in their use in pediatric patients are discussed. Evidence supporting their use for management of gastrointestinal conditions, especially in the pediatric population, is provided when available.
- 21 July 2024
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 79 (3) , 460-472
From the kitchen to the medicine cabinet: Examples of food products and supplements used for therapeutic intent
“Food as medicine” has existed for centuries as the foundation of health for many cultures around the globe. It is a practice built on the knowledge that food and diet play important roles in disease prevention and management. Foods that claim to have therapeutic properties are often referred to as functional foods. These foods contain a number of nutritional and nonnutritional compounds that can interact with pharmacologically relevant receptors, either directly or indirectly via their metabolites, to regulate cellular biochemical processes. Although opinions are changing, the concept of food as a therapeutic intervention goes against conventional Western medicine. To provide guidance to clinicians interested in using these products, members of the Food as Medicine working group of the Nutrition Committee NASPGHAN, as part of a two‐part review series, have created summaries of several frequently used nutritional products for therapeutic intent (i.e., fermented foods, fiber, and long‐chain omega‐3 fatty acids) that includes indications, doses, and caveats. Gaps in their use in pediatric patients are discussed. Evidence supporting their use for management of gastrointestinal conditions, especially in the pediatric population, is provided when available.